Table 1.

Schedule for data collection; outcome measures per visits

Items	Phase Ι: screening	Phase II: baseline	Phase III: 1 month	Phase Ⅳ: 3 months	Phase Ⅴ: 6 months
Inclusion/exclusion criteria	√
Diagnostic index	√
Signed informed consent	√
Randomisation and allocation	√
Safety index	√	√	√	√
General clinical information		√		√
Primary outcomes		√		√
Secondary outcomes		√		√
Other indicators		√		√
Recurrent cardiovascular events			√	√	√
Adherence			√	√	√
Adverse events			√	√
Summary at the end of the study					√